Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v2-FR
Language French French
Date Updated 2022-12-12 2021-09-08
Drug Identification Number 02362449 02362449
Brand name SANDOZ LOSARTAN HCT SANDOZ LOSARTAN HCT
Common or Proper name LOSARTAN HCT LOSARTAN HCT
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM
Strength(s) 12.5MG 100MG 12.5MG 100MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100FCT BO 100FCT BO
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2021-09-08 2021-09-08
Estimated end date 2022-12-09 Unknown
Actual end date 2022-12-07
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments